 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Collateral Therapeutics, Inc.
 |
Collateral Therapeutics, Inc. |
 |
 |
 |
PROFILE |
 |
Collateral Therapeutics develops gene therapy products for the treatment of various cardiovascular diseases as an alternative to such invasive therapies as coronary bypass surgery and angioplasty. Its lead drug candidate is Generx, which promotes angiogenesis (the growth of new blood vessels) in patients with coronary artery disease. The company has teamed with Schering AG to develop and, pending regulatory approval, market the drug. Collateral Therapeutics is also developing drugs that target peripheral vascular disease, congestive heart failure, and ischemic heart disease. It has licensed technology from the University of California and New York University, among others.
COMPETITION |
 |
GenVec, Inc. (GNVC)
Oxford BioMedica plc (OXB)
Vasomedical, Inc. (VASO)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 2.00
1-Yr. Sales Growth: (68.8)%
Employees: 66
Revenue per employee: $30,303.03
KEY PEOPLE |
 |
Jack W. Reich
CEO
Christopher J. Reinhard
CFO
CONTACT INFO |
 |
11622 El Camino Real
San Diego, CA 92130
US
Phone: 858-794-3400
Fax: 858-794-3440
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |